Clinical Trials

Study Title

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Purpose

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

For more information please visit: https://clinicaltrials.gov/study/NCT03615235

Interested in more information on clinical research? Contact WK Health System Clinical Research Department 318-212-8130

Eligibility

Study Process